High-performance liquid chromatographic assays for the quantification of amikacin in human plasma and urine

Papp, E; Knupp, Catherine A.; Barbhaiya, Rashmi H.

doi:10.1016/0378-4347(92)80102-v

Cited by 34 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean steady-state pharmacokinetic parameters of cefepime are given in Table 1 (18). Prior to initiation of the present study, it was determined that cefepime does not affect the potency of amikacin in plasma and urine (20). The results for the analysis of the study QC samples also indicated that there is no detectable chemical interaction between cefepime and amikacin.…”

Section: Resultsmentioning

confidence: 64%

Lack of pharmacokinetic interaction between cefepime and amikacin in humans

Barbhaiya

Knupp

Pfeffer

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The interaction potential between cefepime and amikacin was investigated in a steady-state pharmacokinetic study in 16 healthy male subjects. Eight subjects (group A) received a first course of 2,000 mg of cefepime; this was followed by a second course of 2,000 mg of cefepime with 300 mg of amikacin and a third course of 2,000 mg of cefepime. Eight other subjects (group B) received a first course of 300 mg of amikacin, a second course of 300 mg of amikacin with 2,000 mg of cefepime, and a third course of 300 mg of amikacin. Each course consisted of four consecutive doses administered every 8 h as 30-min intravenous infusions. Serial plasma and urine samples, which were collected after administration of the fourth dose of each course, were assayed for cefepime and/or amikacin by validated high-performance liquid chromatographic assays. Trough levels of cefepime and amikacin indicated that these antibiotics attained a steady state prior to administration of the fourth dose of each course. Key pharmacokinetic parameters for each antibiotic were determined by noncompartmental methods. The peak concentrations of cefepime and amikacin in plasma when the drugs were given alone were about 160 and 27 ,g/ml, respectively. Levels of each antibiotic in plasma declined, with an apparent half-life of approximately 2.2 h. Urinary recovery of cefepime and amikacin accounted for more than 85% of the administered dose of each antibiotic. Mean renal clearances for cefepime and amikacin ranged from 79 to 95 ml/min and suggested that glomerular filtration is the primary excretion mechanism. The results of the statistical analyses indicated that the pharmacokinetic parameters of cefepime following the concurrent administration of amikacin and following the discontinuation of the amikacin therapy were not significantly altered. Similarly, the pharmacokinetic parameters of amikacin following the concurrent administration of cefepime and following the discontinuation of the cefepime therapy were not significantly altered. Cefepime and amikacin can be coadministered to patients with normal renal function by using the standard recommended dosing regimens.Cefepime (BMY-28142) is a new parenteral cephalosporin with significant potential advantages over other new cephalosporins and nontraditional ,3-lactam antibiotics with respect to its antimicrobial spectrum of activity (12,15). In addition, cefepime appears to have a low affinity for chromosomally derived P-lactamases (23). Clinical experience indicates that cefepime is safe and well tolerated when single or multiple (every 8 or 12 h) doses of 250 to 2,000 mg are given by the intravenous (4, 5) or intramuscular (9) routes of administration. The pharmacokinetics of this cephalosporin are linear (4, 5, 9). Over 80% of the administered dose of cefepime is recovered in urine in an unchanged form (4, 5, 7-9).In the most severely infected patients, empiric therapy consists of the administration of antibacterial therapy before pathogen identification. The standard approach has been to use an ant...

show abstract

Section: Resultsmentioning

confidence: 64%

Lack of pharmacokinetic interaction between cefepime and amikacin in humans

Barbhaiya

Knupp

Pfeffer

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…22 Besides it has been reported that precolumn derivatization with OPA or 1-fluoro-2,4-dinitrobenzene resulted in unstable derivatives. 23,24 In the present study, a simple and new HPLC-FLD method for the determination of amikacin in plasma postinhalation was described. The aim of the present investigation was the determination of amikacin by RP-HPLC using the FMOC-Cl as derivatization agent.…”

Section: Introductionmentioning

confidence: 99%

A Simple and Rapid High Performance Liquid Chromatographic Method with Fluorescence Detection for the Estimation of Amikacin in Plasma ‐ Application to Preclinical Pharmacokinetics

Chang

Peng

Liu

2010

J Chinese Chemical Soc

View full text Add to dashboard Cite

A simple and sensitive reversed-phase liquid chromatographic method has been developed for the determination of amikacin by derivatization. The method is based on the pre-column derivatization of amikacin with 9-fluorenylmethyl chloroformate (FMOC-Cl). Isepamicin was used as the internal standard. The derivatization reaction proceeds in aqueous solution at room temperature with a borate buffer of pH 7.3. The formation of the corresponding derivative of amikacin is instantaneous and it is stable for more than 48 h. Detection was performed by fluorescence. Several factors influencing the derivatization reaction yields were studied and optimized. The system offered the following analytical parameters: limit of detection (LOD) of 90 ng mL -1 (3s), linear correlation coefficient of 0.9998 and linear range response from 0.45 to 21.60 mg·mL -1 . The precision of the method was < 6%. As a preliminary application, the method has been successfully applied to the amikacin determination in parenteral pharmaceutical formulations.

show abstract

“…Most LC methods for the determination of amikacin in various samples required the use of different derivatization reactions to provide adequate detection. First LC analysis of aminoglycosides was involving either pre-or post-column derivatization with o-phthalaldehyde (OPA) [6][7][8] or pre-column derivatization with 1-fluoro-2,4-dinitrobenzene [9], 2,4,6-trinitrobenzene sulphonic acid [10], 1-naphtoyl chloride [11], 1-naphtyl isothiocyanate [12] or 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate [13] prior to UV detection.…”

Section: Introductionmentioning

confidence: 99%